Edesa Biotech ((EDSA)), Inflarx N.V. ((IFRX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and ...

Drawing from research on sepsis and complement biology, they developed the monoclonal antibody vilobelimab to block overactive inflammatory responses in patients with severe inflammatory diseases ...

In a new report posted online in the American Journal of Respiratory and Critical Care Medicine, a global consensus conference of 32 critical care experts with broad international representation and ...

(RTTNews) - InflaRx N.V. (IFRX), a biopharmaceutical company specializing in anti-inflammatory therapeutics, announced on Wednesday that the European Commission or EC has granted marketing ...

New research suggests that alpha-1 antitrypsin could be an effective option for treating those with COVID-related acute respiratory distress syndrome (ARDS). In their study, published in the journal ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...

ARDS is a life-threatening condition marked by severe pulmonary inflammation and fluid accumulation in the lungs. Even with aggressive medical management, 40% of ARDS patients do not survive, and ...

The "Australia Acute Respiratory Distress Syndrome Market Analysis 2025" report has been added to ResearchAndMarkets.com's offering. The Australia Acute Respiratory Distress Syndrome (ARDS) Market is ...

DUBLIN--(BUSINESS WIRE)--The "Global Acute Respiratory Distress Syndrome Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by End-User, Mode of Administration, Treatment Mode, ...

Experts are seeing a significant rise in respiratory issues in newborns lately which concerns first-time parents more In this ...